2025
SJR Q1
JCR Q2 · 2,8
112 matched articles
SCIE
Journal detail
Urologic Oncology: Seminars and Original Investigations
- Publisher
- Elsevier Inc.
- Country
- United States · Northern America
- Type
- journal
- ISSN
-
1078143918732496
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,997
- Quartile Q1
- H-Index 93
- Cites/doc 2,45
- Docs (3y) 813
- Cites (3y) 2.001
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 2,8
- 5Y JIF 2,5
- JCI 0,69
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Oncology Q2
- Urology Q1
Areas
- Medicine
WoS categories
- Oncology | Urology & Nephrology
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q2 | 0,997 | 2,8 | 2,5 | 0,69 | Q2 | 93 |
| 2024 | Q1 | Q2 | 0,855 | 2,3 | 2,3 | 0,72 | Q2 | 89 |
| 2023 | Q1 | Q2 | 0,867 | 2,4 | 2,6 | 0,75 | Q2 | 89 |
| 2022 | Q1 | Q2 | 0,874 | 2,7 | 2,8 | 0,71 | Q2 | 89 |
| 2021 | Q1 | Q3 | 0,818 | 3 | 3,1 | 0,72 | Q2 | 89 |
| 2020 | Q1 | Q2 | 1,15 | 3,5 | 3,5 | 0,73 | Q2 | 89 |
| 2019 | Q1 | Q2 | 1,059 | 2,9 | 2,9 | 0,68 | Q2 | 89 |
| 2018 | — | Q2 | — | 2,9 | 2,9 | 0,59 | Q3 | — |
| 2017 | Q1 | Q1 | 1,202 | 3,4 | 3 | 0,65 | Q2 | 89 |
| 2016 | Q1 | Q1 | 1,313 | 3,7 | 3 | — | — | 89 |
| 2015 | Q1 | Q1 | 1,128 | 2,9 | 2,7 | — | — | 89 |
| 2014 | Q1 | Q2 | 1,049 | 2,8 | 2,8 | — | — | 89 |
| 2013 | Q1 | Q1 | 0,943 | 3,4 | 3,2 | — | — | 89 |
| 2012 | Q1 | Q1 | 0,868 | 3,6 | 3,1 | — | — | 89 |
| 2011 | Q1 | Q1 | 0,806 | 3,2 | 2,8 | — | — | 89 |
| 2010 | Q2 | Q1 | 0,734 | 3,2 | 2,8 | — | — | 89 |
| 2009 | — | Q2 | — | 2,5 | 2,4 | — | — | — |
| 2008 | — | Q2 | — | 2,7 | 2 | — | — | — |
| 2007 | — | Q2 | — | 2,6 | 2 | — | — | — |
| 2006 | — | Q2 | — | 2,1 | — | — | — | — |
| 2005 | — | Q3 | — | 1,1 | — | — | — | — |
| 2004 | — | Q2 | — | 1,4 | — | — | — | — |
| 2003 | — | Q3 | — | 1,2 | — | — | — | — |
| 2002 | — | Q3 | — | 0,8 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | ONCOLOGY | SCIE | Q3 | Q2 | 179/333 |
| 2025 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q2 | 48/134 |
| 2024 | ONCOLOGY | SCIE | Q3 | Q2 | 208/328 |
| 2024 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q2 | 54/133 |
| 2023 | ONCOLOGY | SCIE | Q3 | Q2 | 194/322 |
| 2023 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q2 | 46/126 |
| 2022 | ONCOLOGY | SCIE | Q3 | Q2 | 173/241 |
| 2022 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q2 | 43/88 |
| 2021 | ONCOLOGY | SCIE | Q3 | Q2 | 182/245 |
| 2021 | UROLOGY & NEPHROLOGY | SCIE | Q3 | Q2 | 47/90 |
| 2020 | ONCOLOGY | SCIE | Q3 | Q2 | 153/242 |
| 2020 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q2 | 32/89 |
| 2019 | ONCOLOGY | SCIE | Q3 | Q2 | 146/244 |
| 2019 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q2 | 28/85 |
| 2018 | ONCOLOGY | SCIE | Q3 | Q3 | 127/230 |
| 2018 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q3 | 22/80 |
| 2017 | ONCOLOGY | SCIE | Q2 | Q3 | 100/223 |
| 2017 | UROLOGY & NEPHROLOGY | SCIE | Q1 | Q2 | 12/76 |
| 2016 | ONCOLOGY | SCIE | Q2 | — | 79/217 |
| 2016 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 14/77 |
| 2015 | ONCOLOGY | SCIE | Q2 | — | 105/213 |
| 2015 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 19/77 |
| 2014 | ONCOLOGY | SCIE | Q3 | — | 111/211 |
| 2014 | UROLOGY & NEPHROLOGY | SCIE | Q2 | — | 21/78 |
| 2013 | ONCOLOGY | SCIE | Q2 | — | 72/203 |
| 2013 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 14/77 |
| 2012 | ONCOLOGY | SCIE | Q2 | — | 59/197 |
| 2012 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 11/73 |
| 2011 | ONCOLOGY | SCIE | Q2 | — | 72/196 |
| 2011 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 16/73 |
| 2010 | ONCOLOGY | SCIE | Q2 | — | 65/185 |
| 2010 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 15/69 |
| 2009 | ONCOLOGY | SCIE | Q2 | — | 79/166 |
| 2009 | UROLOGY & NEPHROLOGY | SCIE | Q2 | — | 21/63 |
| 2008 | ONCOLOGY | SCIE | Q3 | — | 72/143 |
| 2008 | UROLOGY & NEPHROLOGY | SCIE | Q2 | — | 20/57 |
| 2007 | ONCOLOGY | SCIE | Q3 | — | 67/132 |
| 2007 | UROLOGY & NEPHROLOGY | SCIE | Q2 | — | 15/55 |
| 2006 | ONCOLOGY | SCIE | Q3 | — | 77/127 |
| 2006 | UROLOGY & NEPHROLOGY | SCIE | Q2 | — | 21/55 |
| 2005 | ONCOLOGY | SCIE | Q4 | — | 109/123 |
| 2005 | UROLOGY & NEPHROLOGY | SCIE | Q3 | — | 37/51 |
| 2004 | ONCOLOGY | SCIE | Q3 | — | 91/123 |
| 2004 | UROLOGY & NEPHROLOGY | SCIE | Q2 | — | 25/52 |
| 2003 | ONCOLOGY | SCIE | Q4 | — | 96/120 |
| 2003 | UROLOGY & NEPHROLOGY | SCIE | Q3 | — | 27/49 |
| 2002 | ONCOLOGY | SCIE | Q4 | — | 98/114 |
| 2002 | UROLOGY & NEPHROLOGY | SCIE | Q3 | — | 34/47 |